Skip to content
ES
MARKETS / NASDAQ / CERT
NASDAQ · SERVICES-PREPACKAGED SOFTWARE · LARGE CAP

Certara, Inc. CERT

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$418.8M
▲ 8.7% YoY
$-1.6M
$94.6M
▲ 19.9% YoY
In brief

What this company does

Certara provides biosimulation science, technology, and consulting services for Model-Informed Drug Development in the global biopharmaceutical and biotech industry. Its Phoenix PK/PD suite is software for managing, analyzing and reporting pharmacokinetic, pharmacodynamic and toxicokinetic data. As of December 31, 2025, the company employed 1,576 professionals in 28 countries, including 1,515 full-time employees and 61 part-time employees. It has worked with more than 2,600 life sciences companies and academic institutions and collaborated on more than 10,000 customer projects in the last decade. Certara was formed in 2008 through the combination of Tripos International and Pharsight Corporation, and Certara, Inc. was incorporated in Delaware on June 27, 2017.

Written from the business description in Certara, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 418.8M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 418.8 · Net income -1.6
200M400M-20M-40M2019202020212022202320242025
Compound annual growth
+7.7%
+11.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−0 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 5.0% · Net -0.4%
5%-10%-20%2019202020212022202320242025
ROE
FY2025 · ROE -0.2%
0.5%1.0%-2.0%-4.0%-6.0%2019202020212022202320242025
Gross margin61.5%
Operating margin5.0%
Net margin-0.4%
Return on assets-0.1%
EBITDAUSD 96.2M

Each USD of equity lost 0 cents this year.

Cash & shareholders
USD 42.6M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 94.6
40M80M2019202020212022202320242025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 42.6
20M40M-200M20192020202320242025
Dividends paid—
Net buybacksUSD 42.6M
Share of profit-2671.5%
Consecutive raises—

USD 42.6M in buybacks went back to shareholders in a year without profit.

Total assetsUSD 1.6B
EquityUSD 1.1B
CashUSD 189.4M
Gross debtUSD 293.1M
Net debtUSD 103.7M
Current ratio2.05×

Net debt stands at 10% of equity.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.40.40.40.30.30.20.2
Operating income $B0.0−0.0−0.00.00.0−0.00.0
EBITDA $B0.10.10.00.00.0−0.00.0
Income tax $B0.0−0.00.00.00.0−0.0−0.0
Net income $B−0.0−0.0−0.10.0−0.0−0.0−0.0
Free cash flow $B0.10.10.10.10.10.00.0
EPS, diluted $−0.01−0.08−0.350.09−0.09−0.37−0.07
Dividend / sh $·······
Payout %·······
ROE %−0.2−1.1−5.21.4−1.4−7.5−1.8
Shares out B0.160.160.160.160.160.15·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 26 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 62 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Prepackaged Software
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2019

Share this section

Download image